The Use of Irvingia Gabonensis (Bush Mango)and Cissus Quadrangularis to Reduce Weight and Blood Lipids

This study has been completed.
Information provided by:
Gateway Health Alliance Identifier:
First received: September 6, 2007
Last updated: NA
Last verified: September 2007
History: No changes posted

Hypothesis: Cissus quadrangularis as well as Irvingia gabonensis are used in weight management and related conditions. This study set out to investigate if a combination of the two could have additional benefits to overweight and obese people.

Condition Intervention
Dietary Supplement: Irvingia/cissus combo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Combining Cissus Quadrangularis and Irvingia Gabonensis on Obesity and Obesity Related Diseases

Resource links provided by NLM:

Further study details as provided by Gateway Health Alliance:

Primary Outcome Measures:
  • Weight change [ Time Frame: 10 weeks ]

Secondary Outcome Measures:
  • Blood lipids Body fat Fasting blood glucose [ Time Frame: 10 weeks ]

Enrollment: 72
Study Start Date: January 2007
Study Completion Date: April 2007
Arms Assigned Interventions
Active Comparator: 1
Comparison of actives for synergy
Dietary Supplement: Irvingia/cissus combo
Other Name: Irvingia cissus combo

Detailed Description:

To assess and compare the effects of administration of Cissus quadrangularis (Linn) and a Cissus quadrangularis /Irvingia gabonensis combination on body weight blood pressure, fasting blood glucose, plasma total and LDL cholesterol in 72 overweight and obese subjects.

The study was a 10 week randomized, double-blind, placebo-controlled design, involving 72 obese or overweight participants. Participants were randomly divided into three groups (24 participants/ group):

Group 1 - Placebo; Group 2 - Cissus quadrangularis (CQ); Group 3 - Cissus quadrangularis and Irvingia gabonensis (CQ-IG).

The placebo (250mg) or active formulations ((150 mg CQ and 250 mg CQ-IG) were administered twice daily before meals. Weight as well as fasting blood was taken at baseline, and at 4, 8 and 10 weeks.

No major dietary changes or exercises were suggested during the study.


Ages Eligible for Study:   19 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • BMI>26kg/m2

Exclusion Criteria:

  • Diabetics
  • Pregnant and lactating
  • Subjects on any other weight loss program
  • Following any specific low calorie diet
  Contacts and Locations
Please refer to this study by its identifier: NCT00526682

Sponsors and Collaborators
Gateway Health Alliance
Principal Investigator: Julius E OBEN, PhD University of Yaounde 1
  More Information

No publications provided Identifier: NCT00526682     History of Changes
Other Study ID Numbers: GHACT010
Study First Received: September 6, 2007
Last Updated: September 6, 2007
Health Authority: Cameroon: Ministry of Public Health

Keywords provided by Gateway Health Alliance:
Weight loss

Additional relevant MeSH terms:
Nutrition Disorders
Body Weight
Signs and Symptoms
Lipid Metabolism Disorders
Metabolic Diseases processed this record on April 16, 2014